

# Bio-Plex Pro Human IgA and IgM SARS-CoV-2 Serology Assays Protocol

## Introduction

This quantitative protocol is for use with Bio-Plex Pro Human IgA and IgM SARS-CoV-2 N/RBD/S1/S2 Serology Assays in measuring antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Researchers can use Bio-Plex Pro Human IgA and IgM SARS-CoV-2 Positive Controls as reference standards to generate ng/ml quantitation values.

## Required Materials

- Bio-Plex Pro Human IgA SARS-CoV-2 Positive Control (Bio-Rad Laboratories, Inc., catalog #12014775)
- Bio-Plex Pro Human IgM SARS-CoV-2 Positive Control (Bio-Rad, #12014776)
- Serology sample diluent (included in each kit)

## Standard Curve Preparation

The positive control comes in ready-to-use liquid form at 250  $\mu$ l and serves as the stock control.

### IgA Standard Curve Preparation

1. Use the ready-to-use IgA positive control as S1.
2. Make threefold serial dilutions from S1 up to seven standard curve points (Figure 1). See Table 1 for expected concentrations.
  - a. Fill tubes for S2–S7 with 140  $\mu$ l serology sample diluent.
  - b. To make S2, add 70  $\mu$ l of S1 to 140  $\mu$ l serology sample diluent.
  - c. Repeat the serial dilution until you reach S7 by adding 70  $\mu$ l of the prior standard curve dilution to 140  $\mu$ l of the next standard curve point.




Fig. 1. IgA or IgM Positive Control standard curve dilution scheme.

**Table 1. Threefold serial dilutions for IgA Positive Control S1–S7 standard curve points.**

Standard Curve Point	N (20)*	RBD (36)*	S1 (28)*	S2 (42)*
	Expected Concentration, ng/ml			
S1	400	300	300	800
S2	133.33	100	100	266.67
S3	44.44	33.33	33.33	88.89
S4	14.81	11.11	11.11	29.63
S5	4.94	3.7	3.7	9.88
S6	1.65	1.23	1.23	3.29
S7	0.55	0.41	0.41	1.1

\* Bead regions.

N, nucleocapsid; RBD, receptor binding domain; S1, spike 1; S2, spike 2.

### IgM Standard Curve Preparation

1. Use the ready-to-use IgM positive control as S1.
2. Make threefold serial dilutions from S1 up to seven standard curve points (Figure 1). See Table 2 for expected concentrations.
  - a. Fill tubes for S2–S7 with 140  $\mu$ l serology sample diluent.
  - b. To make S2, add 70  $\mu$ l of S1 to 140  $\mu$ l serology sample diluent.
  - c. Repeat the serial dilution until you reach S7 by adding 70  $\mu$ l of the prior standard curve dilution to 140  $\mu$ l of the next standard curve point.

For research use only.  
Not for use in diagnostic procedures.

**Table 2. Threefold serial dilutions for IgM Positive Control S1–S7 standard curve points.**

Standard Curve Point	N (20)*	RBD (36)*	S1 (28)*	S2 (42)*
	Expected Concentration, ng/ml			
S1	1,000	1,000	1,000	1,000
S2	333.33	333.33	333.33	333.33
S3	111.11	111.11	111.11	111.11
S4	37.04	37.04	37.04	37.04
S5	12.35	12.35	12.35	12.35
S6	4.12	4.12	4.12	4.12
S7	1.37	1.37	1.37	1.37

\* Bead regions.

N, nucleocapsid; RBD, receptor binding domain; S1, spike 1; S2, spike 2.

**Sample Preparation**

Dilute samples 1:100 by adding 2 µl of sample to 198 µl serology sample diluent.

**Note:** Adjust the sample dilution scheme as needed for very high- and low-level anti-SARS-CoV-2 N/RBD/S1/S2 IgA and IgM samples.

For bead, detection antibody, and streptavidin-phycoerythrin preparation, refer to the Bio-Plex Pro SARS-CoV-2 Serology Assay Quick Guide (10000133854) or Bio-Plex Pro Human SARS-CoV-2 Serology Assays Instruction Manual (10000133853).

Visit [bio-rad.com/SARSCoV2Serology](https://www.bio-rad.com/SARSCoV2Serology) for more information.

BIO-RAD and BIO-PLEX are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.

The Bio-Plex Suspension Array System includes fluorescently labeled microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. by the Luminex Corporation.

For research use only. Not for use in diagnostic procedures.



**Bio-Rad  
Laboratories, Inc.**

Life Science  
Group

**Website** [bio-rad.com](https://www.bio-rad.com) **USA** 1 800 424 6723 **Australia** 61 2 9914 2800 **Austria** 00 800 00 24 67 23 **Belgium** 00 800 00 24 67 23 **Brazil** 4003 0399  
**Canada** 1 905 364 3435 **China** 86 21 6169 8500 **Czech Republic** 00 800 00 24 67 23 **Denmark** 00 800 00 24 67 23 **Finland** 00 800 00 24 67 23  
**France** 00 800 00 24 67 23 **Germany** 00 800 00 24 67 23 **Hong Kong** 852 2789 3300 **Hungary** 00 800 00 24 67 23 **India** 91 124 4029300 **Israel** 0 3 9636050  
**Italy** 00 800 00 24 67 23 **Japan** 81 3 6361 7000 **Korea** 82 2 3473 4460 **Luxembourg** 00 800 00 24 67 23 **Mexico** 52 555 488 7670  
**The Netherlands** 00 800 00 24 67 23 **New Zealand** 64 9 415 2280 **Norway** 00 800 00 24 67 23 **Poland** 00 800 00 24 67 23 **Portugal** 00 800 00 24 67 23  
**Russian Federation** 00 800 00 24 67 23 **Singapore** 65 6415 3188 **South Africa** 00 800 00 24 67 23 **Spain** 00 800 00 24 67 23 **Sweden** 00 800 00 24 67 23  
**Switzerland** 00 800 00 24 67 23 **Taiwan** 886 2 2578 7189 **Thailand** 66 2 651 8311 **United Arab Emirates** 36 1 459 6150 **United Kingdom** 00 800 00 24 67 23

